Evaluation of an albumin-binding domain protein fused to recombinant human IL-2 and its effects on the bioactivity and serum half-life of the cytokine
IBJ-Iranian Biomedical Journal. 2017; 21 (2): 77-83
em Inglês
| IMEMR
| ID: emr-186943
ABSTRACT
Background:
Cancer immunotherapy is a promising strategy for cancer treatment. In this strategy, the immune system is triggered to destroy cancer cells. IL-2 is an important factor in passive cancer immunotherapy that helps modulating some important immune functions. One of the IL-2 limitations is low serum half-life; therefore, repetitive high doses of the injections are required to maintain effective concentrations. High-dose IL-2 therapy results in severe side effects; thus, improvement of its serum half-life would provide therapeutic benefits
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Idioma:
Inglês
Revista:
Iran. Biomed. J.
Ano de publicação:
2017
Similares
MEDLINE
...
LILACS
LIS